Medigene AG: Medigene participates at upcoming virtual conferences

Martinsried/Munich (pta032/18.05.2020/22:00 UTC+2) Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that all mentioned conferences will be conducted virtually due to COVID-19.

ASCO 2020 Virtual Annual Meeting
Date: 29 May - 2 June 2020
Website: https://meetings.asco.org/am/virtual-welcome

BIO International Convention Digital
Date: 8 - 12 June 2020
Website: https://www.bio.org/events/bio-digital

Citi 9th European Healthcare Virtual Conference
Date: 16 - 17 June 2020
Website: http://citiglobalevents.com/european-healthcare/event-summary

AACR Virtual Annual Meeting II 2020
Date: 22 - 26 June 2020
Participation: E-Poster presentation on 22 June from 9:00 am - 06:00 pm (EDT)
Link to abstract: https://bit.ly/3g3Q44H
Poster #3231: "The chimeric co-stimulatory receptor PD1-41BB enhances the function of T cell receptor (TCR)-modified T cells targeting solid tumors"
Website: https://www.aacr.org/meeting/aacr-annual-meeting-2020/aacr-virtual-annual-meeting-ii/

- end of announcement -

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Dr Gary Waanders, Claudia Burmester, Dr Anna Niedl
Tel.: +49 89 2000 3333 01
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 - 89 - 20 00 33 - 33 01
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate